Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina
2026-04-29
Gramine as a Targeted Ferroptosis Inducer in Triple-Negative Breast Cancer
Study Background and Research Question
Triple-negative breast cancer (TNBC) represents a highly malignant subtype of breast cancer, characterized by the absence of estrogen, progesterone, and HER2 receptors. This profile not only limits therapeutic options but also underpins the aggressive clinical trajectory, high recurrence rates, and resistance to conventional chemotherapy observed in TNBC patients (source: paper). Given these challenges, there is a pronounced need for novel, mechanistically distinct approaches to TNBC therapy. Recent research attention has focused on natural compounds for their structural diversity and multi-target potential in cancer biology research. Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) is an indole alkaloid derived from plants, previously noted for anti-inflammatory, antimicrobial, and anticancer properties. However, its role in modulating regulated cell death pathways, specifically ferroptosis, in TNBC had not been thoroughly explored.Key Innovation from the Reference Study
The referenced paper provides a mechanistic leap by revealing that Gramine is not only a potent inhibitor of TNBC cell proliferation but acts through a previously uncharacterized pathway: the induction of ferroptosis via CUL3-mediated ubiquitination of MTDH (Metadherin). Unlike apoptosis or necroptosis, ferroptosis is an iron-dependent, lipid peroxidation-driven form of cell death that is emerging as a promising target in therapy-resistant cancers (source: paper). Crucially, the study demonstrates that Gramine directly interacts with the CUL3 E3 ubiquitin ligase complex, altering its activity toward MTDH. This regulatory axis modulates the stability of MTDH, which in turn governs key ferroptosis suppressors and markers, distinguishing Gramine as a unique ferroptosis inducer with translational relevance for aggressive breast cancers.Methods and Experimental Design Insights
To dissect Gramine’s anticancer mechanism, the investigators performed a systematic screening of 27 indole alkaloids using CCK-8 assays to assess cytotoxicity across TNBC cell lines. Gramine emerged as the lead compound with selective toxicity (IC50 ≈ 22–28 μM) against TNBC cells (source: paper). Target identification was achieved through a combination of label-free proteomics (LIP-MS), molecular docking, and biophysical binding assays (CETSA and DARTS), confirming direct Gramine–CUL3 interaction. Western blot analyses quantified the expression of MTDH, SLC3A2, and GPX4, while ferroptosis was monitored via increased ROS, Fe2+, malondialdehyde (MDA), and characteristic mitochondrial morphological changes. Mechanistic validation included ferroptosis rescue experiments (using established ferroptosis inhibitors) and MTDH knockdown. In vivo efficacy was evaluated in 4T1 and MDA-MB-231 xenograft mouse models, with tumor growth and systemic toxicity as endpoints.Protocol Parameters
- CCK-8 viability assay | 22–28 μM (IC50 for Gramine) | TNBC cell lines | Selective inhibition of TNBC proliferation | paper
- Ferroptosis marker assay (ROS, Fe2+, MDA) | Increase relative to control | TNBC and xenograft models | Confirms ferroptosis induction | paper
- Western blot for MTDH, SLC3A2, GPX4 | Dose-dependent downregulation (except MTDH stabilization) | Cellular and in vivo models | Elucidates axis and downstream effectors | paper
- CETSA/DARTS for target engagement | Direct binding of Gramine to CUL3 | Biophysical validation | Supports specificity | paper
- In vivo xenograft dosing | Workflow recommendation: Use 10–50 mg/kg (based on typical alkaloid studies) | Murine models | For assessing tumor suppression and toxicity | workflow_recommendation
- Compound preparation | Gramine soluble in DMSO (≥17.4 mg/mL), ethanol (≥4.41 mg/mL) | For in vitro and animal studies | Ensures reliable dosing and bioavailability | product_spec
Core Findings and Why They Matter
The core outcome of this study is that Gramine substantially inhibits TNBC cell growth both in vitro and in vivo, with minimal systemic toxicity (source: paper). Mechanistically, Gramine disrupts CUL3-mediated ubiquitination of MTDH, resulting in increased MTDH stability. This event downregulates key ferroptosis inhibitors (SLC3A2, GPX4), while upregulating ferroptosis markers such as ROS, Fe2+, and MDA, and decreasing glutathione (GSH) levels. Morphological evidence from electron microscopy revealed mitochondrial condensation and cristae loss, consistent with ferroptosis. Ferroptosis rescue and MTDH knockdown experiments reversed Gramine’s cytotoxic effects, confirming the specificity of this pathway. This research not only establishes Gramine as a unique ferroptosis inducer but identifies the CUL3–MTDH axis as a tractable target for overcoming chemoresistance. The translational significance lies in the prospect of integrating Gramine or derivatives into combination regimens or as a targeted probe in cancer biology research (source: paper).Comparison with Existing Internal Articles
Several internal resources have previously highlighted the mechanistic novelty and workflow applications of Gramine, reinforcing the robustness of these findings:- Gramine Triggers Ferroptosis in Triple-Negative Breast Cancer via CUL3–MTDH Axis offers a concise summary of the reference study’s mechanistic insights, aligning with the evidence that Gramine acts specifically through the CUL3–MTDH ubiquitination pathway.
- Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitination further contextualizes these results within the broader landscape of TNBC research, noting the expansion of ferroptosis-related strategies.
- Gramine: A Precision Ferroptosis Inducer for Cancer Biology Research and Gramine: Mechanistic Insights and Protocols for Cancer Research both provide technical workflows and optimization tips for experimentalists aiming to leverage Gramine’s unique properties in laboratory settings.